Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice
- PMID: 31993314
- PMCID: PMC6976990
- DOI: 10.1016/j.apsb.2019.10.009
Impact of obese levels on the hepatic expression of nuclear receptors and drug-metabolizing enzymes in adult and offspring mice
Abstract
The prevalence of obesity-associated conditions raises new challenges in clinical medication. Although altered expression of drug-metabolizing enzymes (DMEs) has been shown in obesity, the impacts of obese levels (overweight, obesity, and severe obesity) on the expression of DMEs have not been elucidated. Especially, limited information is available on whether parental obese levels affect ontogenic expression of DMEs in children. Here, a high-fat diet (HFD) and three feeding durations were used to mimic different obese levels in C57BL/6 mice. The hepatic expression of five nuclear receptors (NRs) and nine DMEs was examined. In general, a trend of induced expression of NRs and DMEs (except for Cyp2c29 and 3a11) was observed in HFD groups compared to low-fat diet (LFD) groups. Differential effects of HFD on the hepatic expression of DMEs were found in adult mice at different obese levels. Family-based dietary style of an HFD altered the ontogenic expression of DMEs in the offspring older than 15 days. Furthermore, obese levels of parental mice affected the hepatic expression of DMEs in offspring. Overall, the results indicate that obese levels affected expression of the DMEs in adult individuals and that of their children. Drug dosage might need to be optimized based on the obese levels.
Keywords: 18-HA, adult mice fed with 18 weeks HFD; 18-LA, adult mice fed with 18 weeks LFD; 4-HA, adult mice fed with 4 weeks HFD; 4-LA, adult mice fed with 4 weeks LFD; 7-ER, 7-ethoxyresorufin; 8-HA, adult mice fed with 8 weeks HFD; 8-LA, adult mice fed with 8 weeks LFD; AhR, aryl hydrocarbon receptor; BMI, body mass index; CAR, constitutive androstane receptor; CHZ, chlorzoxazone; CYP2E1, cytochrome P450 2E1; DIO, diet-induced obesity; DMEs, drug-metabolizing enzymes; Diet-induced obesity; Drug-metabolizing enzymes; EFV, efavirenz; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; HFD, high-fat diet; HNF4α, hepatocyte nuclear factor 4 alpha; High-fat diet; LFD, low-fat diet; MDZ, midazolam; MPA, mobile phase A; MPB, mobile phase B; NADPH, nicotinamide adenine dinucleotide phosphate; NAFLD, non-alcoholic fatty liver disease; NRs, nuclear receptors; Nuclear receptors; O-18-HA, offspring from parental mice fed with 18 weeks HFD; O-18-LA, offspring from parental mice fed with 18 weeks LFD; O-4-HA, offspring from parental mice fed with 4 weeks HFD; O-4-LA, offspring from parental mice fed with 4 weeks LFD; O-8-HA, offspring from parental mice fed with 8 weeks HFD; O-8-LA, offspring from parental mice fed with 8 weeks LFD; Ontogenic expression; Overweight; PBS, phosphate-buffered saline; PPARα, peroxisome proliferator-activated receptor alpha; PXR, pregnane X receptor; RSF, resorufin; RT-qPCR, real-time quantitative PCR; SD, standard deviation; SULT1A1, sulfotransferase 1A1; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.
© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Figures
Similar articles
-
Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters.Life Sci. 2011 Jul 4;89(1-2):57-64. doi: 10.1016/j.lfs.2011.05.005. Epub 2011 May 18. Life Sci. 2011. PMID: 21620874 Free PMC article.
-
Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.Int J Obes (Lond). 2019 Aug;43(8):1620-1630. doi: 10.1038/s41366-018-0212-0. Epub 2018 Oct 3. Int J Obes (Lond). 2019. PMID: 30283077
-
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.Arch Toxicol. 2008 Dec;82(12):959-64. doi: 10.1007/s00204-008-0312-z. Epub 2008 May 17. Arch Toxicol. 2008. PMID: 18488193 Free PMC article.
-
Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.Curr Drug Metab. 2002 Oct;3(5):481-90. doi: 10.2174/1389200023337171. Curr Drug Metab. 2002. PMID: 12369894 Review.
-
Induction of phase I, II and III drug metabolism/transport by xenobiotics.Arch Pharm Res. 2005 Mar;28(3):249-68. doi: 10.1007/BF02977789. Arch Pharm Res. 2005. PMID: 15832810 Review.
Cited by
-
Metabolism-Disrupting Chemicals and the Constitutive Androstane Receptor CAR.Cells. 2020 Oct 15;9(10):2306. doi: 10.3390/cells9102306. Cells. 2020. PMID: 33076503 Free PMC article. Review.
-
Bilirubin Levels Are Negatively Correlated with Adiposity in Obese Men and Women, and Its Catabolized Product, Urobilin, Is Positively Associated with Insulin Resistance.Antioxidants (Basel). 2023 Jan 11;12(1):170. doi: 10.3390/antiox12010170. Antioxidants (Basel). 2023. PMID: 36671031 Free PMC article.
-
Dietary-Induced Low-Grade Inflammation in the Liver.Biomedicines. 2020 Dec 9;8(12):587. doi: 10.3390/biomedicines8120587. Biomedicines. 2020. PMID: 33317065 Free PMC article.
-
17β-Estradiol protects female rats from bilateral oophorectomy-induced nonalcoholic fatty liver disease induced by improving linoleic acid metabolism alteration and gut microbiota disturbance.Heliyon. 2024 Apr 2;10(7):e29013. doi: 10.1016/j.heliyon.2024.e29013. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38601573 Free PMC article.
-
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD.Oxid Med Cell Longev. 2021 Oct 27;2021:6889533. doi: 10.1155/2021/6889533. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34745420 Free PMC article. Review.
References
-
- World Health Organization. reportObesity: preventing and managing the global epidemic. Report of a WHO consultation (WHO Technical Report Series 894). Available from: https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/. - PubMed
-
- World Health Organization. Fact sheets: obesity and overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
-
- Zhang Y.X., Wang Z.X., Zhao J.S., Chu Z.H. The current prevalence and regional disparities in general and central obesity among children and adolescents in Shandong, China. Int J Cardiol. 2017;227:89–93. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials